Eloralintide + Tirzepatide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Mar 2024: Trial registered, NCT06297616
  2. 15 Apr 2024: Trial started, NCT06297616

The trials

NCT06297616: A Study of LY3841136 in Japanese Participants With Obesity or Overweight

State
Completed
Phase
Phase 1
People
128 taking part
Started
15 Apr 2024
Primary completion
21 Nov 2025
Arms
Part B: LY3841136 + Tirzepatide
Results
None posted
  1. 7 Mar 2024: Trial registered
  2. 15 Apr 2024: Trial started
  3. 21 Nov 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.